Can we move towards personalised pancreatic cancer therapy?

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 4, 2014, Pages 335-338

  Jamieson, Nigel Balfour ^a,b   Chang, David K ^a,c,d,e,f   Grimmond, Sean M ^a,g   Biankin, Andrew V ^a,c,d,e,f  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

actionable phenotypes; genomics; pancreatic cancer; sequencing; stratified medicine; translational research

Indexed keywords

ANTINEOPLASTIC AGENT; CO 101; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; RUCAPARIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; MONOTHERAPY; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERSONALIZED MEDICINE; PHENOTYPE; REVIEW; ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; GENETICS; GENOMICS; MORTALITY; PANCREATIC NEOPLASMS; TRENDS;

ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; PANCREATIC NEOPLASMS;

EID: 84898981167     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.893820     Document Type: Review

References (28)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1):11-30
2. Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet 2013; 14(10):703-18
3. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216): 1061-8
4. International Cancer Genome Consortium. Hudson TJ, Anderson W, Artez A, et al. International network of cancer genome projects. Nature 2010;464(7291):993-8
5. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012;491(7424):399-405
6. Yachida S, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression. Oncogene 2013;32(45): 5253-60
7. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321(5897):1801-6
8. Jamieson NB, Carter CR, McKay CJ, Oien KA. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res 2011;17(10):3316-31
9. Marechal R, Bachet JB, Mackey JR, et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012;143(3):664-74; e1-6
10. Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009;136(1):187-95
11. Poplin EA, Wasan H, Rolfe L, et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol 2013;31(35):4453-61
12. Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 2007;39(2):159-61 (Pubitemid 46184344)
13. Byrski T, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009; 115(2):359-63
14. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817-25
15. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013;500(7463): 415-21
16. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25(15):1960-6 (Pubitemid 46972777)
17. da Cunha Santos G, Dhani N, Tu D, et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: national Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 2010;116(24):5599-607
18. Harder J, Ihorst G, Heinemann V, et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer 2012;106(6):1033-8
19. Chou A, Waddell N, Cowley MJ, et al. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med 2013;5(8):78
20. Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25(3):319-25 (Pubitemid 350003021)
21. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29(34):4548-54
22. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369(18):1691-703
23. The Global Alliance for Genomics and Health. Available from: http:// genomicsandhealth.org/ [Last accessed 27 March 2014]
24. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7(5):469-83 (Pubitemid 40719130)
25. Dennis C. Mouse 'avatars' could aid pancreatic cancer therapy. 2012. Available from: www.nature.com/news/mouse-avatarscould- aid-pancreatic-cancer- therapy-1.10259 [Last accessed 3 January 2014]
26. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011; 10(1):3-8
27. Hidalgo M, Bruckheimer E, Rajeshkumar NV, et al. A pilot clinical study of treatment guided by personalized tumor grafts in patients with advanced cancer. Mol Cancer Ther 2011;10(8): 1311-16
28. Pajic M, Scarlett CJ, Chang DK, et al. Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Hum Genet 2011;130(1): 93-101